All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During the European Hematology Association Hybrid Congress 2024, Jean-Jacques Kiladjian delivered a presentation on the correlation between JAK2V617F molecular response (MR) and event-free survival (EFS) in early polycythemia vera (PV).1 The final data from the phase III PROUD-PV and CONTINUATION-PV trials were used to assess this correlation, as well as the impact of ropeginterferon (ropeg) alfa-2b on EFS.1 |
Key learnings1 |
The probability of EFS during the study periods was significantly higher in patients who experienced a MR at a hazard ratio (HR) of 0.24 (95% confidence interval [CI], 0.07–0.83; p = 0.02). |
Time spent in MR was higher in patients treated with ropeg alfa-2b compared with hydroxyurea or best available therapy (BAT) at 66.7% vs 8.4%, respectively (p = 0.01). |
A higher JAK2V617F allele burden was associated with an increased risk of events at an HR of 1.042 (95% CI, 1.023–1.062; p = 0.0001), equating to 4.2% increased risk of events per 1% increase in variant allele frequencies. |
These data suggest that a 10% decrease in allele burden could correspond with a 34% decreased risk of events. |
Treatment with ropeg alfa-2b was associated with higher rates of <1% JAK2V617F allele burden, achieved in 20.7% of patients compared with 1.4% in the control arm (p = 0.0001). |
Overall, findings from these trials suggest that there is a correlation between MR and EFS, as well as JAK2V617F and EFS, both of which could be extended with the use of ropeg alfa-2b. |
Your opinion matters
Subscribe to get the best content related to MPN delivered to your inbox